Zygocotyle lunata as a model for in vivo screening of anthelmintic activity against paramphistomes: Evaluation of efficacy of praziquantel, albendazole and closantel in experimentally infected mice.

Paramphistomes are important parasites in veterinary medicine. There are few anthelmintic drugs available against them. The development of new drugs is urgently needed and this process can be accelerated through the development of rodent models for in vivo testing. Among the few paramphistomes that develop in rodents is the caecal fluke Zygocotyle lunata, a species with which several biological studies have been performed over several decades. Nevertheless, its use as a model for evaluation of anthelmintic drugs had not yet been evaluated. In the present study, we evaluated the efficacy of praziquantel (PZQ 300 mg/kg 5x), albendazole (ABZ 200 mg/kg 5x) and closantel (CLO 50 mg/kg single dose, 50 mg/kg 3x and 25 mg/kg 3x) for treatment of mice experimentally infected with Z. lunata. The animals were infected with 20 metacercariae of the parasite and were treated 30 days post-infection. Untreated groups were maintained as controls. Seven days after the treatments, the animals were euthanized for recovery and counting of parasites. We found that PZQ and ABZ, at the dosages and therapeutic schedule employed here, did not cause significant alterations in worm burden [worm counts 16.0 ±â€¯2.8 (13-19), 17.6 ±â€¯2.1 (14-19) and 16.2 ±â€¯1.9 (13-18) (p = 0.51) in PZQ, ALB and control, respectively]. CLO 50 mg/kg in a single dose caused significant reduction in the number of parasites [treated: 1.8 ±â€¯0.9 (1-3); control: 15.6 ±â€¯2.5 (12-19)], although it did not result in complete elimination of the parasites in any animal. Despite the fact that three doses of CLO 50 mg/kg or CLO 25 mg/kg caused complete elimination of the parasites in most surviving animals, there was significant host mortality. In general, results here obtained are concordant with those of studies performed on ruminant paramphistomes. Given that Z. lunata can be maintained in laboratory rodents, it is a suitable model for screening anthelmintic drugs against paramphistomes.

Experimental avian philophthalmosis: Evaluation of diagnosis and treatment of chickens infected with Philophthalmus gralli (Trematoda: Philophthalmidae).

The trematodes of the genus Philophthalmus are eye flukes that cause damage to ocular structures of animals and humans. Despite the increasing number of cases reported in birds, studies related to the diagnosis of subclinical philophthalmosis are lacking, and there are no effective therapeutic regimens available. In the present study, we evaluated the diagnosis and treatment of philophthalmosis in specific pathogen-free chickens (Gallus gallus domesticus) experimentally infected with Philophthalmus gralli. Four chickens were inoculated with metacercariae of P. gralli (20 per eye) obtained from cercariae emerged from naturally infected Melanoides tuberculata. From 90 days post-infection, the chickens were subjected to direct ophthalmic examination (DOE) and conjunctival sac lavage (CSL). The latter technique consisted of lavage of each eye with 200 µL sterile saline solution and subsequent microscopical examination of the collected fluid for the presence of eggs of P. gralli. The anthelminthic treatment protocols included praziquantel (PZQ) at 10, 50, or 100 mg/kg (single dose given intramuscularly), or fenbendazole (FBZ) at 50 mg/kg (three doses at 24 h-intervals given per os). The treatment protocols were performed at 14 day-intervals between each dosage of PZQ. Chickens developed a minimum of one to more than five adult P. gralli per eye, except for one chicken that had a single eye with one parasite. No ocular clinical signs or changes in behavior were noted in any chickens. DOE and CSL were considered techniques with similar sensitivity for the diagnosis of avian philophthalmosis. The data suggested that PZQ and FBZ, at the dosages and schedules employed, are not effective for the complete elimination of P. gralli. CSL is proposed as a complementary technique for the diagnosis and monitoring of philophthalmosis post-treatment, especially in subclinical cases. The evaluation of new protocols, routes of administration, and anthelmintic drugs are needed for successful pharmacological treatment of philophthalmosis.